Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.44 |
| ▸ | NMT2 | O60551 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL20493565 | 0.92 | SLC15A2 (0.47) | SLC15A2FOLH1SLC6A5CPB2NMT2 | |
| Valine SCHEMBL18613837 | 0.92 | SLC15A2 (0.47) | SLC15A2FOLH1SLC6A5CPB2NMT2 | |
| SCHEMBL30263767 | 0.90 | SLC15A2 (0.47) | SLC15A2FOLH1SLC6A5CPB2 | |
| SCHEMBL30155353 | 0.90 | SLC15A2 (0.44) | SLC15A2FOLH1SLC6A5CPB2NMT2 | |
| SCHEMBL31202999 | 0.90 | SLC15A2 (0.45) | SLC15A2FOLH1SLC6A5CPB2 | |
| Leucine SCHEMBL20493630 | 0.90 | ERAP2 (0.48) | SLC15A2FOLH1SLC6A5CPB2NMT2 | |
| Leucine SCHEMBL18613476 | 0.90 | ERAP2 (0.48) | SLC15A2FOLH1SLC6A5CPB2NMT2 | |
| SCHEMBL29638074 | 0.90 | SLC15A2 (0.47) | SLC15A2FOLH1SLC6A5CPB2NMT2 | |
| Isoleucine SCHEMBL20493995 | 0.89 | CPB2 (0.45) | SLC15A2FOLH1SLC6A5CPB2NOD1 | |
| Isoleucine SCHEMBL18613635 | 0.89 | CPB2 (0.45) | SLC15A2FOLH1SLC6A5CPB2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743102-A1 | COLLAGEN PEPTIDE COMPOSITION AND USE THEREOF IN AMELIORATING NEUROLOGICAL CONDITIONS AND FIBROSIS | Rousselot BV (BE) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026087731-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMINO ACID COMPOSITION IN PURIFIED HYALURONIC ACID | INTIBIO BV (BE) | 2026-04-30 | — | — | WO | disclosed |
| US-20250319152-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-11589603-B2 | Powdered nutritional product containing branched-chain amino acids and a sugar alcohol | ABBOTT LABORATORIES (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2022211624-A1 | TAILOR-MADE FUNCTIONALIZED SELF-ASSEMBLED PEPTIDE (NANO)FIBERS AND HYDROGELS, AND METHODS, USES AND KITS RELATED THERETO | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022092284-A1 | COMPOSITION CONTAINING LIPID PEPTIDE AND SUCROSE ESTER | 日産化学株式会社 | 2022-05-05 | — | — | WO | disclosed |
| WO-2022065433-A1 | COSMETIC FOR HAIR | 日産化学株式会社 | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319152-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | ARG2, TNNT2, MYLK2 | SLC15A2 1697/4885FOLH1 436/4885SLC6A5 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.